Oxidative stress protection by novel telomerase activators in mesenchymal stem cells derived from healthy and diseased individuals

Current Molecular Medicine

Volumn 13, Issue 6, 2013, Pages 1010-1022

  Tichon, A ^a   Eitan, E ^a   Kurkalli, B G ^b   Braiman, A ^a   Gazit, A ^c   Slavin, S ^b   Beith Yannai, E ^a   Priel, E ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Human mesenchymal stem cells; Oxidative stress; Telomerase; TERT activators

Indexed keywords

5' NUCLEOTIDASE; AGS 499; AGS 500; DACTINOMYCIN; ENDOGLIN; NEUROPROTECTIVE AGENT; TELOMERASE REVERSE TRANSCRIPTASE; THY 1 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL SURVIVAL; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DNA DAMAGE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MALE; MESENCHYMAL STEM CELL; NORTHERN BLOTTING; OXIDATIVE STRESS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84881354630     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524011313060013     Document Type: Article

References (71)

1. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98: 1076-1084.
2. Zeitouni S, Ford BS, Harris SM, Whitney MJ, Gregory CA, Prockop DJ. Pharmaceutical induction of ApoE secretion by multipotent mesenchymal stromal cells (MSCs). BMC Biotechnol 2008; 8: 75.
3. Kasper G, Mao L, Geissler S, et al. Insights into mesenchymal stem cell aging: involvement of antioxidant defense and actin cytoskeleton. Stem Cells 2009; 27: 1288-1297.
4. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
5. Hamada H, Kobune M, Nakamura K, et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 2005; 96: 149-156.
6. Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev 2006; 5: 91-116.
7. Zheng H, Martin JA, Duwayri Y, Falcon G, Buckwalter JA. Impact of aging on rat bone marrow-derived stem cell chondrogenesis. J Gerontol A Biol Sci Med Sci 2007; 62: 136-148.
8. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003; 108: 457-463.
9. Wang YQ, Wang M, Zhang P, et al. Effect of transplanted mesenchymal stem cells from rats of different ages on the improvement of heart function after acute myocardial infarction. Chin Med J (Engl) 2008; 121: 2290-2298.
10. Boker W, Yin Z, Drosse I, et al. Introducing a single-cell-derived human mesenchymal stem cell line expressing hTERT after lentiviral gene transfer. J Cell Mol Med 2008; 12: 1347-1359.
11. Nakahara H, Misawa H, Hayashi T, et al. Bone repair by transplantation of hTERT-immortalized human mesenchymal stem cells in mice. Transplantation 2009; 88: 346-353.
12. Wang Z, Deng Q, Zhang X, Zhang J. Treatment of injured neurons with bone marrow stem cells cotransfected by hTERT and Ad-BDNF in vitro. J Mol Neurosci 2009; 38: 265-272.
13. Collins K, Mitchell JR. Telomerase in the human organism. Oncogene 2002; 21: 564-579.
14. Smogorzewska A, de Lange T. Regulation of telomerase by telomeric proteins. Annu Rev Biochem 2004; 73: 177-208.
15. Urquidi V, Tarin D, Goodison S. Role of telomerase in cell senescence and oncogenesis. Annu Rev Med 2000; 51: 65-79.
16. Kang HJ, Choi YS, Hong SB, et al. Ectopic expression of the catalytic subunit of telomerase protects against brain injury resulting from ischemia and NMDA-induced neurotoxicity. J Neurosci 2004; 24: 1280-1287.
17. Massard C, Zermati Y, Pauleau AL, et al. hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway. Oncogene 2006; 25: 4505-4514.
18. Ahmed S, Passos JF, Birket MJ, et al. Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress. J Cell Sci 2008; 121: 1046-1053.
19. Haendeler J, Drose S, Buchner N, et al. Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial DNA and function from damage. Arterioscler Thromb Vasc Biol 2009; 29: 929-935.
20. Cong Y, Shay JW. Actions of human telomerase beyond telomeres. Cell Res 2008; 18: 725-732.
21. Stellwagen AE, Haimberger ZW, Veatch JR, Gottschling DE. Ku interacts with telomerase RNA to promote telomere addition at native and broken chromosome ends. Genes Dev 2003; 17: 2384-2395.
22. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. Cell 2003; 114: 241-253.
23. Swiggers SJ, Nibbeling HA, Zeilemaker A, Kuijpers MA, Mattern KA, Zijlmans JM. Telomerase activity level, but not hTERT mRNA and hTR level, regulates telomere length in telomerase-reconstituted primary fibroblasts. Exp Cell Res 2004; 297: 434-443.
24. Hosseini-Asl S, Modarressi MH, Atri M, Salhab M, Mokbel K, Mehdipour P. The association between telomerase activity and expression of its RNA component (hTR) in breast cancer patients: the importance of DNase treatment. J Carcinog 2006; 5: 17.
25. Flores I, Benetti R, Blasco MA. Telomerase regulation and stem cell behaviour. Curr Opin Cell Biol 2006; 18: 254-260.
26. Stocum DL, Zupanc GK. Stretching the limits: stem cells in regeneration science. Dev Dyn 2008; 237: 3648-3671.
27. Tichon A, Gowda BK, Slavin S, Gazit A, Priel E. Telomerase activity and expression in adult human mesenchymal stem cells derived from amyotrophic lateral sclerosis individuals. Cytotherapy 2009; 11: 837-848.
28. Ju Z, Jiang H, Jaworski M, et al. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. Nat Med 2007; 13: 742-747.
29. Liu L, DiGirolamo CM, Navarro PA, Blasco MA, Keefe DL. Telomerase deficiency impairs differentiation of mesenchymal stem cells. Exp Cell Res 2004; 294: 1-8.
30. Sahin E, Colla S, Liesa M, et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011; 470: 359-365.
31. de Jesus BB, Schneeberger K, Vera E, Tejera A, Harley CB, Blasco MA. The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell 2011; 10: 604-621.
32. Jaskelioff M, Muller FL, Paik JH, et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 2011; 469: 102-106.
33. Eitan E, Tichon A, Gazit A, Gitler D, Slavin S, Priel E. Novel telomerase-increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis. EMBO Mol Med 2012; 4: 313-329.
34. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
35. Konnikova L, Simeone MC, Kruger MM, Kotecki M, Cochran BH. Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res 2005; 65: 6516-6520.
36. Mah LJ, Orlowski C, Ververis K, Vasireddy RS, El-Osta A, Karagiannis TC. Evaluation of the efficacy of radiation-modifying compounds using gammaH2AX as a molecular marker of DNA double-strand breaks. Genome Integr 2011; 2: 3.
37. Liu Y, Snow BE, Hande MP, et al. The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr Biol 2000; 10: 1459-1462.
38. Li CD, Zhang WY, Li HL, et al. Mesenchymal stem cells derived from human placenta suppress allogeneic umbilical cord blood lymphocyte proliferation. Cell Res 2005; 15: 539-547.
39. Maxson S, Burg KJ. Conditioned media cause increases in select osteogenic and adipogenic differentiation markers in mesenchymal stem cell cultures. J Tissue Eng Regen Med 2008; 2: 147-154.
40. Tirosh A, Potashnik R, Bashan N, Rudich A. Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J Biol Chem 1999; 274: 10595-10602.
41. Gordon D, Pavlovska G, Uney JB, Wraith DC, Scolding NJ. Human mesenchymal stem cells infiltrate the spinal cord, reduce demyelination, and localize to white matter lesions in experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol 2010; 69: 1087-1095.
42. Park HJ, Bang G, Lee BR, Kim HO, Lee PH. Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy parkinsonism. Cell Transplant 2011; 20: 827-835.
43. Vercelli A, Mereuta OM, Garbossa D, et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2008; 31: 395-405.
44. Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B. Aging of mesenchymal stem cell in vitro. BMC Cell Biol 2006; 7: 14.
45. Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004; 22: 675-682.
46. Kurz DJ, Decary S, Hong Y, Trivier E, Akhmedov A, Erusalimsky JD. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J Cell Sci 2004; 117: 2417-2426.
47. Ju Z, Lenhard Rudolph K. Telomere dysfunction and stem cell ageing. Biochimie 2008; 90: 24-32.
48. Mangerini R, Lanino E, Terranova P, et al. Telomere length of donors influences granulocyte recovery in children after hematopoietic stem cell transplantation. Ann Hematol 2009; 88: 1029-1031.
49. Ozawa K, Sato K, Oh I, et al. Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun 2008; 30: 121-127.
50. Eitan E, Tichon A, Gazit A, Gitler D, Slavin S, Priel E. Novel telomerase-increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis. EMBO Mol Med 2012; 4: 313-329.
51. Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001; 107: 67-77.
52. Baykal A, Thompson JA, Xu XC, et al. In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues. Oncol Rep 2004; 11: 297-302.
53. Ernst A, Okkels H, Grove A, et al. Telomerase activity determined by conventional telomeric repeat amplification protocol and reverse transcriptase-polymerase chain reaction assay in ovarian lesions: a comparison of assays. Scand J Clin Lab Invest 2006; 66: 287-297.
54. Liu J, Baykal A, Fung KM, et al. Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ. Int J Oncol 2004; 24: 879-884.
55. Yasumoto S, Kunimura C, Kikuchi K, et al. Telomerase activity in normal human epithelial cells. Oncogene 1996; 13: 433-439.
56. Bollmann FM. The many faces of telomerase: emerging extratelomeric effects. Bioessays 2008; 30: 728-732.
57. Saretzki G. Telomerase, mitochondria and oxidative stress. Exp Gerontol 2009; 44: 485-492.
58. Haendeler J, Hoffmann J, Brandes RP, Zeiher AM, Dimmeler S. Hydrogen peroxide triggers nuclear export of telomerase reverse transcriptase via Src kinase family-dependent phosphorylation of tyrosine 707. Mol Cell Biol 2003; 23: 4598-4610.
59. Del Bufalo D, Rizzo A, Trisciuoglio D, et al. Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. Cell Death Differ 2005; 12: 1429-1438.
60. Jin X, Beck S, Sohn YW, et al. Human telomerase catalytic subunit (hTERT) suppresses p53-mediated anti-apoptotic response via induction of basic fibroblast growth factor. Exp Mol Med 2010; 42: 574-582.
61. Sharma GG, Gupta A, Wang H, et al. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene 2003; 22: 131-146.
62. Ebert R, Ulmer M, Zeck S, et al. Selenium supplementation restores the antioxidative capacity and prevents cell damage in bone marrow stromal cells in vitro. Stem Cells 2006; 24: 1226-1235.
63. Song H, Cha MJ, Song BW, et al. Reactive oxygen species inhibit adhesion of mesenchymal stem cells implanted into ischemic myocardium via interference of focal adhesion complex. Stem Cells 2010; 28: 555-563.
64. Yang YJ, Qian HY, Huang J, et al. Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts. Arterioscler Thromb Vasc Biol 2009; 29: 2076-2082.
65. Kaufmann SH, Svingen PA. Immunoblot analysis and band depletion assays. Methods Mol Biol 1999; 94: 253-268.
66. Sambrook J, Fritch E, Maniatis T. Molecular cloning: A laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press 1989.
67. Ishigami M, Swertfeger DK, Granholm NA, Hui DY. Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase. J Biol Chem 1998; 273: 20156-20161.
68. Chin RK, Zhu M, Christiansen PA, et al. Lymphotoxin pathway-directed, autoimmune regulator-independent central tolerance to arthritogenic collagen. J Immunol 2006; 177: 290-297.
69. Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 2007; 25: 1384-1392.
70. Eruslanov E, Kusmartsev S. Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol 2010; 594: 57-72.
71. Ueyama H, Horibe T, Hinotsu S, et al. Chromosomal variability of human mesenchymal stem cells cultured under hypoxic conditions. J Cell Mol Med 2011; 16: 72-82.